Gene · 57721
Papers4,298
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
2,261 to 2,280 of 4,298
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The role of m6A methylation in osteosarcoma biological processes and its potential clinical value. | Hum Genomics | 2022 | 35436972 | PubTator, text mining | PubMed |
| Increased m6A modification of lncRNA DBH-AS1 suppresses pancreatic cancer growth and gemcitabine resistance via the miR-3163/USP44 axis. | Ann Transl Med | 2022 | 35433957 | PubTator, text mining | PubMed |
| Risk Score Prediction Model of Prognosis in GC Patients by Age and Gender Combined With m6A Modification Genes FTO and RBM15. | Front Cell Dev Biol | 2022 | 35433701 | PubTator, text mining | PubMed |
| Identification of LncRNA Prognostic Signature Associated With Genomic Instability in Pancreatic Adenocarcinoma. | Front Oncol | 2022 | 35433487 | PubTator, text mining | PubMed |
| An m6A-Related lncRNA Signature Predicts the Prognosis of Hepatocellular Carcinoma. | Front Pharmacol | 2022 | 35431958 | PubTator, text mining | PubMed |
| TSPAN31 regulates the proliferation, migration, and apoptosis of gastric cancer cells through the METTL1/CCT2 pathway. | Transl Oncol | 2022 | 35429902 | PubTator, text mining | PubMed |
| The role of epigenetic modifications in Colorectal Cancer Metastasis. | Clin Exp Metastasis | 2022 | 35429301 | PubTator, text mining | PubMed |
| Metabolic Remodeling Impacts the Epigenetic Landscape of Dental Mesenchymal Stem Cells. | Stem Cells Int | 2022 | 35422867 | PubTator, text mining | PubMed |
| N6-methyladenosine Modification-Related Long Non-Coding RNAs are Potential Biomarkers for Predicting the Prognosis of Patients With Osteosarcoma. | Technol Cancer Res Treat | 2022 | 35422168 | PubTator, text mining | PubMed |
| Comprehensive Analysis Revealed the Potential Implications of m6A Regulators in Lung Adenocarcinoma. | Front Mol Biosci | 2022 | 35419413 | PubTator, text mining | PubMed |
| N6-methyladenosine modification of CENPK mRNA by ZC3H13 promotes cervical cancer stemness and chemoresistance. | Mil Med Res | 2022 | 35418160 | PubTator, text mining | PubMed |
| Inducible and reversible RNA N6-methyladenosine editing. | Nat Commun | 2022 | 35414049 | PubTator, text mining | PubMed |
| Analysis of the function and mechanism of DIRAS1 in osteosarcoma. | Tissue Cell | 2022 | 35413492 | PubTator, text mining | PubMed |
| Chemical biology and medicinal chemistry of RNA methyltransferases. | Nucleic Acids Res | 2022 | 35412633 | PubTator, text mining | PubMed |
| Long noncoding RNA lnc-H2AFV-1 promotes cell growth by regulating aberrant m6A RNA modification in head and neck squamous cell carcinoma. | Cancer Sci | 2022 | 35403343 | PubTator, text mining | PubMed |
| Alteration of N6-Methyladenosine mRNA Methylation in a Human Stem Cell-Derived Cardiomyocyte Model of Tyrosine Kinase Inhibitor-Induced Cardiotoxicity. | Front Cardiovasc Med | 2022 | 35402566 | PubTator, text mining | PubMed |
| Molecular subtypes of m6A RNA methylation modification patterns and their clinical significance in clear cell renal cell carcinoma. | Transl Cancer Res | 2022 | 35402182 | PubTator, text mining | PubMed |
| m6A-induced repression of SIAH1 facilitates alternative splicing of androgen receptor variant 7 by regulating CPSF1. | Mol Ther Nucleic Acids | 2022 | 35402071 | PubTator, text mining | PubMed |
| Comprehensive Analysis of YTHDF1 Immune Infiltrates and ceRNA in Human Esophageal Carcinoma. | Front Genet | 2022 | 35401696 | PubTator, text mining | PubMed |
| RNA N6-Methyladenosine Modifications and Its Roles in Alzheimer's Disease. | Front Cell Neurosci | 2022 | 35401117 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/57721/papers?page=114